The effect of upper respiratory tract diseases on phonation has been reviewed, but little is known about the influence of lower respiratory tract diseases. In particular, the effect of asthma as a reversible obstructive small-airway disease on phonatory variables is not yet clear. We conducted a cross-sectional controlled study to evaluate the quality of phonation in a group of 34 adults with untreated mild to severe persistent asthma who were seen at the Ghaem Hospital in Mashhad, Iran. Patients with sinusitis, gastroesophageal reflux disease, or primary laryngeal disease were ineligible for study participation. For comparison purposes, we identified a group of nonasthmatic, ageand sex-matched healthy controls. We evaluated eight voice parameters: basal voice frequency at the glottic level (F0), jitter, shimmer, breathiness, harshness, hoarseness, normalized noise energy (NNE), and S/Z ratio. These parameters were measured by a voice meter with Dr. Speech statistical software. We found that values for F0, jitter, and shimmer were very similar in the two groups, but there were statistically significant differences in values for harshness, hoarseness, NNE, S/Z ratio (all p < 0.01), and breathiness (p = 0.015). Our findings suggest that lower airway diseases such as asthma can impair phonation, and we recommend future studies with larger populations to further explore this issue.
Introduction
The effects of small-airway diseases on phonation have not been investigated a great deal, and only a few such studies have been published in the international literature. As a result, our understanding of the effects of asthma on phonation is incomplete. Asthma is a reversible obstructive small-airway disease that affects 4 to 5% of the general population. 1 Reversibility has been defined as a 12 to 15% increase in forced expiratory volume in 1 second (FEV 1 ) with the use of 2 puffs of a short-acting beta-2 agonist. 2 In this article, we describe our study of changes in various voice parameters brought about by asthma. To the best of our knowledge, our study is one of the first investigations of untreated adult-onset asthma in nonallergic patients. Our selection criteria allowed us to exclude from our patient population most factors that might interfere with the effect of asthma on the upper respiratory tract. Investigations into the relationship between lower airway diseases and phonation is a new field of study and one that we believe is important.
Patients and methods
Patients and controls. We performed a cross-sectional controlled study to evaluate voice features in 34 patients-16 men and 18 women, aged 20 to 72 (mean: 39.5)-who had been diagnosed with Global Initiative for Asthma 3 (GINA) step 2, 3, or 4 asthma between March 20 and September 20, 2008-basically from the beginning of spring through the end of summer. According to the GINA rating system, the degree of asthma is classified into four categories called steps: step 1 is intermittent asthma, step 2 is mild persistent asthma, step 3 is moderate persistent asthma, and step 4 is severe persistent asthma. 3 None of these patients had received any previous treatment for asthma, either because they had not sought treatment or because they were newly diagnosed.
Exclusion criteria included previous or current gastroesophageal reflux disease, sinusitis, or primary laryngeal diseases in the glottic or subglottic area. The presence of reflux was determined by history taking and questioning about typical and atypical symptoms of reflux, including regurgitation, substernal chest pain, heartburn, sore throat, and hiccups. The presence of sinusitis was denoted by a history of postnasal discharge or active rhinorrhea or by radiologic findings. The presence of laryngeal diseases was determined by history taking and indirect or fiberoptic laryngoscopy.
For these 34 patients, information was compiled on smoking, employment status, onset of symptoms, history of allergy, nasal spray use, nocturnal symptoms (awakening from sleep caused by asthma), functional activity (e.g., ability to walk up stairs), and social function. Also, spirometric indexes-the FEV 1 and forced vital capacity (FVC) ratio, the percentage of predicted FEV 1 , and the change in FEV 1 after bronchodilator treatment-were measured, and x-ray and computed tomography (CT) imaging was obtained. None of the patients smoked, none had a history of allergy, and none used a nasal spray.
For comparison purposes, we identified a control group of 34 subjects-18 men and 16 women, aged 20 to 50 years (mean: 35.1). In addition to sex and age (table 1), the controls were matched for their lack of history of reflux, sinusitis, primary laryngeal disease, smoking, allergy, and nasal spray use.
Voice parameters. Voice evaluations included measurements of eight voice parameters: basal voice frequency (F0), jitter, shimmer, breathiness, harshness, hoarseness, normalized noise energy (NNE), and S/Z ratio. 4, 5 F0 is the voice frequency at the glottic level in Hz. Jitter represents the change in voice frequency from cycle to cycle; it is expressed as a percentage, with the upper limit of normal being 0.5%. Shimmer represents the change in voice intensity from cycle to cycle; it, too, is expressed as a percentage, with the upper limit of normal being 3%. Breathiness is a manifestation of air loss during phonation. Harshness indicates a deviation from normal voice, which can include vibration. Hoarseness encompasses both breathiness and harshness. Breathiness, harshness, and hoarseness are graded on a scale of 0 to 3, with higher grades indicating more deviation from normal. 5,6 NNE, or glottal noise, represents noise energy at the time of phonation; testing identifies differences between harmonies and produced vocal signals. The S/Z ratio is an indication of the length of time patients can sustain the sounds S and Z; normal patients have a ratio in the range of 1.0 to 1.4.
Recordings were made on Dr. Speech software (Tiger DRS; Seattle) while patients and controls produced the EE vowel sound in front of a microphone. Dr. Speech software is a comprehensive speech/voice assessment and training instrument that provides quantitative information for analyzing voice disorders. This software has been normalized for Iranian patients. 4 The noise level of the testing room was acceptable (<40 dB), and the microphone was fixed 5 cm from the mouth. Each test was performed three times, and the longest duration greater than 5 seconds was used for analysis.
Data were analyzed with the two-tailed t test and the chi-squared test by a biostatistician for statistically significant differences between the two groups. Informed consent was obtained from patients and controls, and our institution's ethics committee approved the study protocol.
Results
Chest x-ray findings were normal in all the asthma patients. Their mean duration of symptoms prior to diagnosis was 13.8 months, and their mean incidence of nocturnal symptoms was 1.3 times per month. The spirometric findings in the asthma group are shown in table 2. Analysis of the eight voice parameters revealed that there were statistically significant differences between the asthma group and the controls in five of them: breathiness (p = 0.015), harshness (p = 0.001), hoarseness (p < 0.001), NNE (p = 0.002), and S/Z ratio (p = 0.005) (table 3) . Values for F0, jitter, and shimmer were similar in the two groups.
Discussion
Williamson et al compared dysphonia in 255 asthma patients and 100 normal healthy controls. 7 They found that dysphonia was present in 58% of the asthma patients who were using an inhaled corticosteroid. The prevalence of dysphonia in the control group was 13%. Symptoms were more common in women than in men. Higher doses of steroids were associated with more severe symptoms, and 34% of the asthma patients reported aerosol-induced cough. Ihre et al studied 350 asthma patients and reported corticosteroid-induced dysphonia in 80%. 8 Balter et al examined 77 asthma patients who were treated with inhaled beclomethasone (1,000 µg/day) over a 4-month period and compared them with 10 asthma patients who did not receive this treatment. 9 They found no intergroup difference in jitter, but the shimmer value was significantly better in the beclomethasone group (p < 0.05). Bhalla et al compared the results of inhaled corticosteroid treatment in 46 asthma patients and found that jitter and shimmer were abnormal in patients who regularly used an inhaled corticosteroid compared with those who were not regular users. 10 In our study, we selected patients who had not received any asthma medication in order to control for the effects of medication. The fact that we did not see any difference between the asthma patients and the controls in F0, jitter, and shimmer likely indicates that asthma patients have a normal phonatory mechanism at the level of the vocal folds.
In a study somewhat similar to ours, Dogan et al found that jitter and shimmer values were significantly higher in asthma patients than in controls, as was the harmonics-to-noise ratio. 11 The differences between the findings of that study and our findings might be attributable to the presence of vocal fold myopathy among the asthma patients who received inhaled steroid treatment in the former study. 12 Our finding that breathiness, harshness, hoarseness, NNE, and S/Z ratio were all abnormal in asthma patients suggests to us that the lower airway does play a role in the phonation process as a producer of positive air pressure in the subglottic area. Abnormalities in the lower airway may lead to voice roughness and harshness with increased air loss (a higher breathiness score) and decreased phonation time at the larynx (a higher S/Z ratio).
Air loss in asthma patients can be brought about by an abnormal glottic closure pattern. 11 This in turn can lead to greater losses of vocal energy in the form of noise production (a higher NNE value). Dogan et al found that maximum phonation time in asthma patients was significantly less than that of controls (p < 0.001) because the asthma patients did not exhibit the laryngeal movement required for maximal phonation. 11 Finally, Govindaiah et al reported dysphonia in 4 of 9 asthma patients (44.4%) and in 39 of 84 patients with both asthma and allergic rhinitis (46.4%), but unlike our study, theirs included patients with reflux disease and those with chronic asthma who had been under treatment. 13 In conclusion, our results suggest that lower airway disease can disturb phonation. In our study, breathiness, harshness, hoarseness, NNE, and S/Z ratio were all significantly worse in the asthma patients than in the controls. Further investigation may help us better understand the pathophysiology of lower airway diseases and their effects on voice parameters. We suggest further studies with larger samples to evaluate the effect of asthma therapies on phonation among asthma patients. posteroinferior portion of the septum. 6 This patient had bilateral otitis media with effusion, septal deviation, adenoid hypertrophy, and hypertrophy of the posterior ends of both inferior conchae. The patient was treated with adenoidectomy and septoplasty. The authors speculated that there might be an association between vomeral agenesis and ear problems. They suggested that turbulent airflow and compensatory adenoid hypertrophy created by the os vomer defect might have predisposed this patient to ear disease. We did not encounter any ear pathology in our patient. Other cases of congenital vomeral defects have been reported by Lee, 7 by Kang et al, 2 and by Herrero Calvo et al. 8 Yilmaz and Altuntaş 6 and Herrero Calvo et al 8 agreed that these defects are probably more prevalent than what has been suggested in the literature and that the increasingly frequent use of nasal endoscopy will lead to an increase in the number of diagnoses. As far as we know, our case is only the fourteenth such case that has been reported in the literature (table). 
